Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function
Completed · Phase 1
Conditions studied: Renal Impairment
In brief
This is an open-label, single dose study designed to assess the pharmacokinetics and safety of ABT-493 and ABT-530 in subjects with either normal renal function or impaired renal function.
Key facts
- Study ID
- NCT02442258
- Run by
- AbbVie
- People needed
- 46
- Starts
- 2015-03-01
- Expected to finish
- 2015-12-01
- Last updated by the study team
- 2016-02-22
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Site Reference ID/Investigator# 132890 — Miami, Florida, United States
- Site Reference ID/Investigator# 132889 — Orlando, Florida, United States
- Site Reference ID/Investigator# 137332 — Grafton, Auckland, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.